Clovis sinks as rociletinib questions linger

Clovis Oncology Inc. (NASDAQ:CLVS) lost $3.40 (18%) to $15.77 on Friday after FDA reviewers asked an advisory committee whether the company will need to submit more data before the agency decides whether to approve lung cancer candidate rociletinib ( CO-1686). The panel is also

Read the full 444 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE